JPMorgan's latest research report indicates that the widespread adoption of GLP-1 weight-loss drugs is fundamentally reshaping the underlying logic of Asia's consumer sector. The core of this transformation is a deeper behavioral shift, where business models relying on impulse, habit, and convenience-driven consumption are facing systemic pressure.
According to JPMorgan, as the appetites of GLP-1 users change, the impact extends far beyond high-calorie foods. It disrupts a consumption chain built on craving, convenience, habit, social permission, and repeat purchases, a chain that a significant portion of Asia's consumer industry growth is based on monetizing. In a sample of 533 current users across China, India, and South Korea, approximately 75% reduced their snack intake, 62% cut down on alcohol consumption, 69% of tobacco users lowered their usage, 74% ordered fewer takeaways, and 84% reported a significant decline in the desire for impulse purchases or "treating themselves." Spending during social and festive occasions also contracted sharply.
Meanwhile, consumers' wallets haven't closed; instead, spending has been redirected. The survey data shows that while users cut back on snacks, fast food, takeaways, alcohol, and impulse buys, they increased spending on home cooking, fruits and vegetables, protein supplements, fitness, health check-ups, activewear, and some beauty and medical aesthetics. Consumption has shifted from "triggered" to "goal-oriented": controlling what is consumed, maintaining weight loss results, or making the changes visible to oneself and others.
In terms of current profit and loss statements, the EPS of Asian consumer stocks has not yet been impacted. GLP-1 penetration in Asia remains low, and this survey is not a penetration forecast. However, valuations may not wait for the profit and loss statement to confirm before moving. For consumer companies reliant on frequency, habit, repeat purchases, and operating leverage, multiples could react first if investors begin to question whether future transactions will be as easy to generate.
What is weakened is not a specific category, but "instant and stimulus-driven consumption."
The survey reveals that GLP-1's impact goes far beyond simply reducing food intake. Across the three markets, 85% of respondents reported decreased appetite, but the more significant investment implication is the broad contraction in consumer behavior. This survey sample covers 175 people in China, 183 in India, and 175 in South Korea, all current GLP-1 users. 56% have been using it for over six months, 91% reported weight loss of at least 3 kg since starting, and 85% reported decreased appetite. The most significant cuts were in categories driven by craving, indulgence, and instant reward: 79% reduced snacks, 77% cut fried foods, and 70% reduced sugary drinks. This pattern spanned vastly different eating habits – Chinese users reduced bubble tea, Indian users cut instant noodles, pizza, and traditional sweets, and South Korean users reduced fried chicken, side dishes, and baked goods. While local products varied, the behavioral direction was highly consistent. More notably, this restraint extended to categories with no direct link to calorie intake: 62% of respondents reduced alcohol consumption, and nearly 70% of tobacco users consumed less. 84% of respondents said their desire to "treat themselves" or engage in impulse shopping had decreased, indicating a broader effect on desire rather than a simple dietary adjustment.
JPMorgan attributes this phenomenon to a single underlying logic: these categories depend on consumers saying "yes without thinking." Desire triggers consumption, convenience completes the transaction, occasions provide permission, and repetition builds value. This mechanism is precisely where Asia's consumer industry has been most effective at monetization. GLP-1 disrupts every link in this chain: decreased appetite weakens the trigger, the reduced desire to "treat oneself" softens impulse, restraint during social and festive occasions renders "occasion permission" ineffective, and convenience can no longer reliably convert weakened desires into transactions.
The risk to takeaways and fast food goes beyond smaller order values.
If consumers were merely eating less, companies could partially offset the impact through smaller portions, price increases, product mix adjustments, or low-sugar, high-protein formulas. The more challenging scenario is the disappearance of the transaction itself. In the sample, 79% reported reduced spending or frequency on fast food, 74% reduced takeaway spending or frequency, and 68% increased home cooking. China's data is particularly telling: in a market with a highly developed takeaway system, 74% still reduced their takeaway orders, and 80% increased home cooking. This suggests that convenience no longer automatically translates into transaction conversion. The growth logic of many past consumption models was to reduce friction – closer stores, faster delivery, smoother payments, easier menus. This logic presupposed that consumers already had the desire. GLP-1 weakens the front-end trigger; even if the back-end is seamless, it may not be able to pull in orders. Social and festive occasions also lack a natural moat. In the sample, 92% of users reported that social dining was affected, and 89% said festive consumption decreased or became more restrained. Many still attend gatherings or holiday events, but they eat and drink less and order more carefully. For dining, alcohol, gifting, and shared consumption, the risk is not just that individual users have smaller appetites, but also that it can impact total table spending, the frequency of reorders, and the efficiency of social occasions in driving sales. JPMorgan's report categorizes the risk into three layers: average transaction value risk (still buying, but buying less), frequency risk (buying less often), and scenario risk (the occasion for consumption itself disappears). Frequency risk is harder to hedge than transaction value risk, and scenario risk is even more difficult to defend against than frequency risk.
Money has been redirected: from instant gratification to control and visible progress.
GLP-1 users haven't stopped spending; they are just directing their money towards goals. The most significant growth was seen in spending related to controlling the process, maintaining results, and making changes visible: 62% increased spending on gyms or fitness classes, 58% on supplements or protein products, 51% on medical care or health check-ups, 44% on activewear or sports shoes, 40% on skincare or beauty, and 31% on medical aesthetics. Furthermore, 84% reported increased exercise frequency, and 68% increased home cooking. These categories are not all "health food." Sports shoes are not medicine, skincare is not weight loss, and medical aesthetics are not nutrition. However, they all serve the same consumer task: enabling users to control the process, maintain results, or make changes more visible. JPMorgan summarizes this as "control is the new convenience." The old convenience was making it easier for desire to become a purchase; the new convenience is making it easier to stick with progress. In the sample, 26% increased spending on travel, 18% on gold or jewelry, and around 17% on personal electronics, luxury accessories, and perfumes. Money saved from food and beverages is being purposefully redistributed from trigger-based consumption to goal-oriented consumption. Applying this framework to stocks, the core question is not "which sector does the company belong to," but rather "how much of its growth comes from consumers' automatic 'yes'?" JPMorgan categorizes companies into three groups. The first group consists of companies reliant on "thoughtless" consumption, where demand comes from frequency, habit, craving, or social occasions – these are expected to be negatively impacted. The second group includes companies in transition, such as those expanding into nutrition, protein, and functional foods. The third group comprises companies with goal-oriented demand at their core. The latter two groups are expected to benefit.
The valuation debate may precede the earnings impact.
The current major boundary condition is clear: GLP-1 is not yet a P&L issue for the Asian consumer sector. The sample is a behavioral survey of current users, not a penetration forecast; the data is self-reported changes, not proof of causation. However, multiples for consumer stocks often capitalize future frequency, repeat purchases, store efficiency, and customer lifetime value. Once investors begin to question these assumptions, the profit and loss statement might lag, but valuations may not. The survey contains several warning signals that could make investors cautious: 89% of users plan to continue using GLP-1 for at least six to twelve months; 71% have already recommended GLP-1 to others; and 79% expect that at least some of their new habits will persist even after stopping. Gallup data shows that GLP-1 usage among U.S. adults is projected to rise from about 3% in 2024 to 11% by 2026, with a cumulative usage rate of 15%. Once oral formulations, domestic production, price reductions, and expanded distribution channels take hold, adoption rates in Asia could accelerate. JPMorgan highlighted three key timelines to watch: first, the arrival of oral GLP-1s in Asia – Novo's oral Wegovy was approved in the U.S. in December 2025, and Eli Lilly's orforglipron was approved in the U.S. in April 2026. According to JPMorgan's pharma team, orforglipron could be approved in China as early as late 2026 to early 2027. Second, the first batch of domestically produced semaglutide in China is expected to be approved from 2027 onwards, with over a dozen local companies potentially driving price competition and market expansion. Third, consumer companies may begin launching products specifically for GLP-1 users, such as muscle-preserving protein and portion-controlled packaging. Once operators start redesigning products for these users, the market can no longer treat it as a purely pharmaceutical issue. Ultimately, the question is not whether GLP-1 will cause all consumer stocks to fall. The real question is more specific: which companies have profited from consumers' impulses, and which have profited from consumers' goals? The former needs to prove it isn't solely reliant on frequency and occasion; the latter needs to prove that goal-oriented spending is repeatable. Valuation divergence may start from here.
Comments